Genomictree Inc.
228760
Ранг среди акций
#19260
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Цена акции
$6.57
Рыночная капитализация
$161.24M
Изменение (1 день)
-0.63%
Изменение (1 год)
-51.24%
Страна
KR
Торговля Genomictree Inc. (228760)
Категория
Healthcare
Рыночная капитализация Genomictree Inc.(228760)
Рыночная капитализация: $161.24M
По состоянию на October 2026 рыночная капитализация Genomictree Inc. составляет $161.24M. Согласно нашим данным, Genomictree Inc. занимает 19260th место среди самых ценных компаний мира по рыночной капитализации. Рыночная капитализация — это общая рыночная стоимость всех находящихся в обращении акций публичной компании и обычно используется для оценки ее стоимости.
История рыночной капитализации Genomictree Inc. с 2017 по 2026
228760 по сравнению с пятеркой самых популярных stocks
